Physician profile
Thomas Johnson
NPI 1922090430
$5,297.38
in general payments reported to CMS, 2019-2025
32 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $422 · 2021: $630 · 2022: $597 · 2023: $816 · 2024: $810 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,670 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,670.37 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,555.49 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Genzyme Corporation | $699.36 | 2019-2023 | |
| Glaxosmithkline, LLC. | $421.54 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $407.13 | 2019-2025 | |
| Abbvie INC. | $366.78 | 2021-2023 | |
| Biocryst US Sales Co., LLC | $298.58 | 2023-2025 | Orladeyo |
| Pharming Healthcare, INC. | $282.63 | 2022-2025 | Ruconest |
| Biohaven Pharmaceuticals, INC. | $211.66 | 2020-2021 | |
| Genentech USA, INC. | $121.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $106.57 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $83.23 | 2021-2023 | Dupixent |
| Grifols USA, LLC | $81.20 | 2019-2021 | |
| Octapharma USA, INC. | $63.26 | 2019-2020 | |
| Leo Pharma INC. | $59.18 | 2022 | |
| Kaleo, INC. | $54.94 | 2022-2023 | Auvi-Q |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44.86 | 2023 | Tezspire |
| Cycle Pharmaceuticals INC | $42.84 | 2024-2025 | Sajazir |
| Biocryst Pharmaceuticals, INC. | $42.11 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.79 | 2021 | |
| Merck Sharp & Dohme LLC | $37.77 | 2019-2021 | |
| Gc Biopharma USA, INC. | $32.09 | 2024 | Alyglo |
| Janssen Pharmaceuticals, INC | $31.63 | 2024 | Spravato |
| Csl Behring | $28.31 | 2024 | Haegarda |
| Ionis Pharmaceuticals, INC. | $25.00 | 2025 | |
| Radius Health, INC. | $24.47 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.21 | 2022 | |
| Galderma Laboratories, L.P. | $17.61 | 2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $16.93 | 2020 | |
| Greer Laboratories, INC. | $14.86 | 2019 | |
| Shire North American Group INC | $14.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.